A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY)

Trial Details

  • 180 patients will be taking part in this study
  • Condition: Crohn's Disease
  • Intervention: Drug: Mirikizumab Drug: Placebo
  • Clinic: Delta Research Partners 608 Grammont Street

Summary

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

Full Trial Details

Researchers

Dr. Raj Bhandari

Gastroenterologist

Raj bhandari headshot for dt trial listings